ArticlePain reports2018

NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain.

Pierre Arsenault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.